Treatment of Recurrent Bronchial Asthma Attacks

Immediate Management of Acute Exacerbations

For recurrent asthma attacks, the American Thoracic Society and other guidelines recommend initiating or intensifying daily inhaled corticosteroid (ICS) therapy as the foundation of treatment, combined with short-acting beta-agonists for acute symptom relief, and add oral corticosteroids (30-40 mg prednisolone daily for 7-21 days) for moderate to severe exacerbations 1, 2, 3
Administer prednisolone 30-40 mg daily until lung function returns to baseline, typically 7-21 days depending on severity, as recommended by the British Medical Journal and American Family Physician 1, 2, 4
Oral corticosteroids are equally effective as intravenous administration and should be the preferred route, according to the British Medical Journal and Praxis Medical Insights 1, 4
No tapering is required for courses under 2 weeks, as stated by the American Family Physician and Praxis Medical Insights 2, 4
Provide repetitive or continuous short-acting beta-agonists via nebulizer or large-volume spacer device depending on severity, as recommended by the British Medical Journal and Journal of Allergy and Clinical Immunology 1, 5
Maintain oxygen saturation >90%, as recommended by Praxis Medical Insights 4

For mild persistent asthma, low-dose ICS is the most effective single long-term control medication, according to the American Family Physician and Journal of Allergy and Clinical Immunology 2, 3, 6
For moderate persistent asthma, the preferred treatment is low-to-medium-dose ICS plus long-acting beta-agonist (LABA), as recommended by the American Family Physician, Journal of Allergy and Clinical Immunology, and Mayo Clinic Proceedings 3, 7, 8, 6
For severe persistent asthma, high-dose ICS plus LABA is the preferred treatment, according to the Journal of Allergy and Clinical Immunology and Mayo Clinic Proceedings 7, 8

SABA use more than 2-3 times daily indicates inadequate control, as stated by the British Medical Journal and American Family Physician 1, 2, 3
Peak expiratory flow dropping below 60% of patient's best, sleep disturbance extending to midday, and diminishing response to inhaled bronchodilators are triggers for treatment intensification, according to the British Medical Journal 1
Verify correct inhaler technique at every visit, as recommended by Praxis Medical Insights 6
Check compliance before any treatment increase, as stated by the British Medical Journal 1

Never use LABAs as monotherapy, as they must always be combined with ICS to avoid increased risk of asthma exacerbations and death, according to the American Family Physician and Praxis Medical Insights 2, 3, 6
Use large-volume spacer devices with doses >800 mcg to reduce local and systemic adverse effects, as recommended by the British Medical Journal 1
Monitor elderly patients more closely for gastrointestinal bleeding risk, especially those with prior bleeding history or on anticoagulants, according to the British Medical Journal and Praxis Medical Insights 1, 4

Provide written asthma action plans instructing patients to recognize early warning signs and adjust medications accordingly, as recommended by the Journal of Allergy and Clinical Immunology 5
Identify and control environmental triggers, such as allergens, smoking, and occupational exposures, according to the British Medical Journal and Mayo Clinic Proceedings 1, 8
Patient education improves knowledge, behavior, and reduces hospitalizations, as stated by the British Medical Journal 1

The British Thoracic Society guidelines state that SABA use more than 2-3 times daily is the trigger for increasing treatment at all stages of asthma management, indicating inadequately controlled asthma and the need for immediate intensification of maintenance therapy 9, 10, 11, 12

Check inhaler technique, as improper technique is a common cause of apparent treatment failure 9, 10, 11, 12
Assess medication compliance, as non-adherence must be addressed before treatment escalation 9, 10, 11, 12

If on low-dose inhaled corticosteroid (ICS) alone, add a long-acting beta-agonist (LABA) to the existing ICS, as this combination is more effective than increasing ICS dose alone for moderate persistent asthma 9, 10, 11, 12
If on ICS dose below 800 mcg/day beclomethasone equivalent, increase the ICS dose up to 800 mcg/day equivalent of beclomethasone, and consider adding a non-steroidal anti-inflammatory agent if the patient cannot tolerate higher ICS doses 9, 10, 11, 12

Document frequency of SABA use, symptom-free days per week, nighttime awakenings due to asthma, limitations on daily activities, and peak expiratory flow measurements to assess treatment efficacy and identify potential issues 9, 10, 11, 12, 13, 14

Reassess in 1-3 months after treatment escalation to determine if the patient has achieved stability on the new regimen and to consider potential stepwise reduction 9, 10, 11, 12

The American Academy of Family Physicians recommends omalizumab for severe persistent allergic asthma in patients who remain uncontrolled despite high-dose ICS-LABA and potentially oral corticosteroids 15
The Journal of Allergy and Clinical Immunology suggests that omalizumab is not appropriate for acute exacerbation management as it takes weeks to months to demonstrate clinical benefit 16, 17

The National Asthma Education and Prevention Program guidelines support the use of prednisone 40-60 mg daily for 5-10 days without tapering for outpatient moderate exacerbations, although the specific citation is not provided, the American family physician and Journal of Allergy and Clinical Immunology recommend verifying proper inhaler technique, assessing medication adherence patterns, and identifying environmental triggers before considering additional controller medications 15, 16, 17
Increasing the frequency of budesonide-formoterol to every 4 hours as needed for symptom relief during the exacerbation is a recommended approach, according to the Journal of Allergy and Clinical Immunology 16, 17

The Journal of Allergy and Clinical Immunology recommends increasing the budesonide dose to medium-dose range (320-640 mcg/day) while continuing formoterol for moderate persistent asthma, or adding a leukotriene receptor antagonist (montelukast 10 mg once daily) to the current budesonide-formoterol regimen 15, 16, 17